title: Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?
authors.forename: Francesco
authors.initials: F
authors.lastname: Locatelli
authors.forename: Pedro
authors.initials: P
authors.lastname: Aljama
authors.forename: Peter
authors.initials: P
authors.lastname: Barany
authors.forename: Bernard
authors.initials: B
authors.lastname: Canaud
authors.forename: Fernando
authors.initials: F
authors.lastname: Carrera
authors.forename: Kai-Uwe
authors.initials: KU
authors.lastname: Eckardt
authors.forename: Iain C
authors.initials: IC
authors.lastname: Macdougall
authors.forename: Alison
authors.initials: A
authors.lastname: Macleod
authors.forename: Walter H
authors.initials: WH
authors.lastname: Hörl
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wiecek
authors.forename: Stewart
authors.initials: S
authors.lastname: Cameron
mesh_terms: D001323:Autoantibodies / Q000187:drug effects* / Q000378:metabolism; D004920:Erythropoiesis / Q000187:drug effects / Q000276:immunology*; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000517:prevention & control; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D018570:Risk Assessment; D012720:Severity of Illness Index
chemical_list: D001323:Autoantibodies; D011994:Recombinant Proteins; D004921:Erythropoietin